Dare Biosciences Inc. (NASDAQ: DARE) stock gained by 23.68% at last close while the DARE stock price rises by 3.72% in the pre-market trading session. Daré Bioscience is a clinical-stage pharmaceutical business dedicated on the development of novel women’s health products. DARE’s objective is to find, create, and bring to market a diversified portfolio of differentiated treatments for women, especially in the areas of contraception, vaginal health, sexual health, and fertility that broaden treatment options, enhance results, and provide convenience.
Dare Bioscience Inc.’s stock soared after the California-based health-care business revealed that it had been given a fresh grant from the Bill and Melinda Gates Foundation for up to $48.95 million. Trading volume increased to 18.1 million shares, compared to an average of around 3.7 million shares for the whole day. Dare’s experimental reversible contraception, DARE-LARC1, will be tested in people thanks to the new funding, which will fund research and preclinical efforts.Dare promised to make DARE-LARC1 and any additional products available at an affordable price to individuals in poor nations, as well as to assist the US educational system and public libraries, according to the grant agreement. Through Tuesday, the stock had dropped 10.6 percent, while the iShares Nasdaq Biotechnology ETF had risen 9.4 percent and the S&P 500 had gained 6.5 percent.
Recent Past Development
Daré Bioscience released good topline findings from their DARE-HRT1 Phase 1 clinical study. DARE-HRT1 is a new IVR that delivers bio-identical 17-estradiol and bio-identical progesterone continuously over a 28-day period as part of a hormone therapy (HT) regimen to cure menopausal vasomotor symptoms and genitourinary syndrome.DARE-HRT1 has the ability to be the first FDA-approved item to deliver vaginal delivery of mix bio-identical estradiol and bio-identical progesterone hormonal treatment in an easy monthly format to treat both VMS and vaginal symptoms of menopause, according to the study’s topline data.
The North American Menopause Society’s hormone therapy guidelines state that combining estrogen and progestogen may provide significant benefits to women, and that non-oral methods of delivery may be preferable than orally given medicines.